FUSILEV
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
Mar 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUSILEV is an intravenous solution approved in 2008 for an undisclosed indication. The drug's mechanism of action and pharmacologic class are not publicly detailed in available data, limiting specificity about its therapeutic role.
LOE Approaching
FUSILEV is approaching loss of exclusivity with moderate competitive pressure (30%), signaling contraction phase requiring defensive positioning and potential team downsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Started Apr 2013
0Non-Small Cell Lung Cancer
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Started Mar 2013
0Non Hodgkin's Lymphoma
Career Relevance
FUSILEV roles are primarily defensive, focused on maximizing exclusivity value and managing the LOE transition. Career mobility is limited due to minimal linked job postings and contracted team size expected during this lifecycle phase.
Brand Manager
Worked on FUSILEV at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.